WallStreetZenWallStreetZen

NYSEMKT: NBY
Novabay Pharmaceuticals Inc Earnings & Revenue

NBY past revenue growth

How has NBY's revenue growth performed historically?
Company
5.66%
Industry
89.08%
Market
19.74%
NBY's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
NBY's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
NBY's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

NBY earnings and revenue history

Current Revenue
$14.2M
Current Earnings
-$18.6M
Current Profit Margin
-130.3%

NBY Return on Equity

Current Company
-389.1%
Current Industry
16.8%
Current Market
28.2%
NBY's Return on Equity (-389.1%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when NBY announces earnings.

NBY Return on Assets

Current Company
-171.6%
Current Industry
3.2%
NBY is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

NBY Return on Capital Employed

Current Company
-775.65%
Current Industry
-42.4%
NBY's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

NBY vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
NBY$14.23M-$10.95M-$18.55M+5.19%N/A
PHIO$0.00-$9.21M-$9.38M-100.00%N/A
CING$0.00-$21.08M-$22.50MN/AN/A
QNRX$0.00-$8.31M-$8.41MN/AN/A
CYCC$449.00k-$22.70M-$19.85M+24.52%N/A

NBY earnings dates

Next earnings date
Aug 8, 2024

Novabay Pharmaceuticals Earnings & Revenue FAQ

What were NBY's earnings last quarter?

On Invalid Date, Novabay Pharmaceuticals (NYSEMKT: NBY) reported Q1 2024 earnings per share (EPS) of -$5.25, up 82.35% year over year. Total Novabay Pharmaceuticals earnings for the quarter were -$3.59 million. In the same quarter last year, Novabay Pharmaceuticals's earnings per share (EPS) was -$29.75.

If you're new to stock investing, here's how to buy Novabay Pharmaceuticals stock.

What was NBY's earnings growth in the past year?

As of Q3 2024, Novabay Pharmaceuticals's earnings has grown year over year. Novabay Pharmaceuticals's earnings in the past year totalled -$18.55 million.

What is NBY's earnings date?

Novabay Pharmaceuticals's earnings date is Invalid Date. Add NBY to your watchlist to be reminded of NBY's next earnings announcement.

What was NBY's revenue last quarter?

On Invalid Date, Novabay Pharmaceuticals (NYSEMKT: NBY) reported Q1 2024 revenue of $2.63 million up 12.48% year over year. In the same quarter last year, Novabay Pharmaceuticals's revenue was $2.34 million.

What was NBY's revenue growth in the past year?

As of Q3 2024, Novabay Pharmaceuticals's revenue has grown 5.66% year over year. This is 83.41 percentage points lower than the US Biotechnology industry revenue growth rate of 89.08%. Novabay Pharmaceuticals's revenue in the past year totalled $14.23 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.